Clinical Performance Comparison of Several Different Contact Lenses
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00912028 |
Recruitment Status :
Completed
First Posted : June 3, 2009
Results First Posted : April 28, 2014
Last Update Posted : June 19, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Myopia | Device: senofilcon A Device: lotrafilcon B Device: balafilcon A Device: methafilcon A Device: vifilcon A | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 71 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Multicenter, Single-masked, Randomized, Parallel, Controlled Study to Compare Senofilcon A Contact Lenses to Currently Used Contact Lenses |
Actual Study Start Date : | May 1, 2009 |
Actual Primary Completion Date : | February 1, 2010 |
Actual Study Completion Date : | February 1, 2010 |

Arm | Intervention/treatment |
---|---|
Active Comparator: senofilcon A
contact lens
|
Device: senofilcon A
contact lens |
Active Comparator: lotrafilcon B
contact lens
|
Device: lotrafilcon B
contact lens |
Active Comparator: balafilcon A
contact lens
|
Device: balafilcon A
contact lens |
Active Comparator: methafilcon A
contact lens
|
Device: methafilcon A
contact lens |
Active Comparator: vifilcon A
contact lens
|
Device: vifilcon A
contact lens |
- Limbal Hyperemia (Redness) [ Time Frame: 2 weeks ]Subject distribution according to limbal hyperemia scale in each eye during the 2-week Follow-up Visit. For this scale, 0 is lowest and 4 is greatest. If present in at least one eye, then it is counted.
- Limbal Hyperemia (Redness) [ Time Frame: 4 weeks ]Subject distribution according to limbal hyperemia scale in each eye during the 4-week Follow-up Visit. For this scale, 0 is lowest and 4 is greatest. If present in at least one eye, then it is counted.
- Bulbar Hyperemia (Redness) [ Time Frame: 2 weeks ]Subject distribution according to bulbar hyperemia scale in each eye during the 2-week Follow-up Visit. For this scale, 0 is lowest and 4 is greatest. If present in at least one eye, then it is counted.
- Bulbar Hyperemia (Redness) [ Time Frame: 4 weeks ]Subject distribution according to bulbar hyperemia scale in each eye during the 4-week Follow-up Visit. For this scale, 0 is lowest and 4 is greatest. If present in at least one eye, then it is counted.
- Corneal Staining [ Time Frame: 2 weeks ]Subject distribution according to corneal staining with fluorescein scale in each eye during the 2-week Follow-up Visit. For this scale, 0 is lowest and 4 is greatest. If present in at least one eye, then it is counted.
- Corneal Staining [ Time Frame: 4 weeks ]Subject distribution according to corneal staining with fluorescein scale in each eye during the 4-week Follow-up Visit. For this scale, 0 is lowest and 4 is greatest. If present in at least one eye, then it is counted.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 39 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Subjects must:
- be existing soft contact lens wearers of the study control lenses
- require a distance visual correction in both eyes
- have a contact lens spherical distance requirement between -1.00 diopters (D) and -8.00D in both eyes
- have astigmatism less than or equal to 1.00D in both eyes
- be able to wear lenses available for this study
- be corrected to a visual acuity of 6/9 (20/30) or better in each eye
- have normal eyes with no evidence of abnormality or disease
Exclusion Criteria:
Subject are excluded for the following reasons:
- monovision corrected
- worn lenses extended wear in the last 3 months.
- require concurrent ocular medication
- grade 3 or 4 abnormalities
- grade 3 corneal staining in more than two regions
- anterior ocular surgery
- any other ocular surgery or injury within 8 weeks prior to study enrollment
- abnormal lachrymal secretions
- pre-existing ocular irritation that would preclude contact lens fitting
- corneal irregularities
- Polymethyl methacrylate (PMMA) or Rigid Gas Permeable (RGP) lens wear in past 12 weeks
- any systemic illness which would preclude contact lens wear
- diabetes
- infectious or immunosuppressive disease
- pregnancy or lactating, or planning pregnancy at time or enrollment
- participating in a concurrent clinical study or within last 60 days
- allergy to the standardized study care solution

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00912028
Brazil | |
Salvador, BA, Brazil, 41810-570 | |
Recife, PE, Brazil, 51020-031 | |
Maringá, PR, Brazil, 87014-110 | |
Rio de Janeiro, RJ, Brazil, 22640-100 | |
Campinas, SP, Brazil, 13092-320 | |
Marilia, SP, Brazil, 17519-030 | |
Ribeirão Preto, SP, Brazil, 14049-900 | |
Santo André, SP, Brazil, 09060-650 | |
São Paulo, SP, Brazil, 04063-000 | |
São Paulo, SP, Brazil, 04534-000 | |
São Paulo, SP, Brazil, 05409-001 |
Principal Investigator: | Carlos E Leite Arieta, MD, PhD | Associate Professor - Ophthalmolgy, University of Campinas, Brazil |
Responsible Party: | Johnson & Johnson Vision Care, Inc. |
ClinicalTrials.gov Identifier: | NCT00912028 |
Other Study ID Numbers: |
AOH--BRA-001 |
First Posted: | June 3, 2009 Key Record Dates |
Results First Posted: | April 28, 2014 |
Last Update Posted: | June 19, 2018 |
Last Verified: | August 2017 |
Myopia Refractive Errors Eye Diseases |